ArticleCase reports in dermatology
Successful Treatment of Chronic
Article in Case reports in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 151 citations in OpenAlex.
- Lack of improvement after short-term topical antistaphylococcal endolysin SA.100 therapy in patients with mild-to-moderate atopic dermatitis: Results from a randomized, vehicle-controlled trial.British journal of clinical pharmacology · 2026Trial
- Trial
- Phage-Derived Endolysins TargetingAntibiotics (Basel, Switzerland) · 2026Review
- Designing the Next Generation of Endolysins: A Triple Strategy Integrating Bioinformatics Mining, Engineering Modification and Encapsulation Formulation.Probiotics and antimicrobial proteins · 2026Review
- Activity and Biocompatibility Evaluation of Enzybiotic Compositions Formulated withInternational journal of molecular sciences · 2026Article
- Innovative Approaches to Combat Antimicrobial Resistance: A Review of Emerging Therapies and Technologies.Probiotics and antimicrobial proteins · 2026Review
- Enhancing stability and safety of chimeric peptidoglycan hydrolases by linker engineering.Applied microbiology and biotechnology · 2026Article
- Clinical implementation of endolysins targeting gram-positive bacteria points toward a combination strategy with standard-of-care antibiotics: a selective review.European journal of medical research · 2026Review
- Innate immune recognition and immunomodulatory effects of bacteriophages: implications for phage therapy.Frontiers in immunology · 2026Review
- Phages as antimicrobials against multi-drug resistant bacteria.Frontiers in microbiology · 2026Review
- Phage Therapy: Application and Related Problems-A Review.Life (Basel, Switzerland) · 2025Review
- The human skin microbiome: from metagenomes to therapeutics.Nature reviews. Microbiology · 2025Review
- Bacteriophages and Endolysins Used in the Biocontrol ofMicroorganisms · 2025Review
- PlyNJ3: a three-domain endolysin with broad-spectrum anti-streptococcal activity and synergistic efficacy against multidrug-resistant Streptococcus suis.BMC veterinary research · 2025Article
- Microbiota-Host Interactions: Exploring Their Dynamics and Contributions to Human Diseases.MicrobiologyOpen · 2025Review
- Activity of GS-linked chimeric endolysin CHAPk-SH3bk against methicillin-resistant Staphylococcus aureus biofilms: an in-vitro, ex-vivo and in-vivo study.NPJ biofilms and microbiomes · 2025Article
- [Phage endolysins-a novel class of antibacterial agents with a wide range of applications].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025Review
- Modifying Pharmacokinetic Properties of the Gram-Negative Bacteria Targeting Endolysin ML06 Without Affecting Antibacterial Activity.International journal of molecular sciences · 2025Article
- Bacteriophages as Targeted Therapeutic Vehicles: Challenges and Opportunities.Bioengineering (Basel, Switzerland) · 2025Review
- Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections.Pharmaceutics · 2025Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.